Caroline Baumal

Executive

Chief Medical Officer

Apellis Pharmaceuticals, Inc.Apellis Pharmaceuticals, Inc.

Insider activity · 24 months0 buys5 salesCumulative net flow

Nov 24 · 0 buys · 0 salesDec 24 · 0 buys · 0 salesJan 25 · 0 buys · 2 salesFeb 25 · 0 buys · 0 salesMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 0 salesJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 0 buys · 0 salesDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 3 salesFeb 26 · 0 buys · 0 salesMar 26 · 0 buys · 0 salesApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 0 buys · 0 salesSept 26 · 0 buys · 0 salesOct 26 · 0 buys · 0 sales

Total declarations

Company

▲ Purchases (0 ops.)

—

▼ Sales (6 ops.)

€447k

Latest filing published 14 May 2026 for Apellis Pharmaceuticals, Inc.. Read the official filing

Filing timeline

BuySale

Caroline Baumal

Insider track record

Disclosed buys

Disclosed sells

Not enough buy signals with a settled T+90 horizon to measure a track record yet.

Signal history

Caroline Baumal: trading record in brief

This profile gathers the share dealings of Caroline Baumal in Apellis Pharmaceuticals, Inc., where the filings describe the role as senior executive. Over a trading history stretching from 3 January 2023 to 14 May 2026, the count stands at 11 filings.

Sales make up the whole of the open-market record (6 sales, €447k). Besides market trades, the filings include 3 share grants. In 2026 alone, the filings show no purchases and 3 sales.

The newest entry dates from 14 May 2026: a transaction, in Apellis Pharmaceuticals, Inc. The median gap between a trade and its publication by SEC (Form 4) is 1 day. US insiders must file a Form 4 within two business days of a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.